Angiotensin-Converting Enzyme Inhibitors: A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.Angiotensin II Type 1 Receptor Blockers: Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.Angiotensin II: An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.Receptor, Angiotensin, Type 1: An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention.Receptors, Angiotensin: Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells.Receptor, Angiotensin, Type 2: An angiotensin receptor subtype that is expressed at high levels in fetal tissues. Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR.Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.Angiotensin Receptor Antagonists: Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.Angiotensin III: A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%).TetrazolesLosartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.Renin-Angiotensin System: A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.Peptidyl-Dipeptidase A: A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.Antihypertensive Agents: Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.Renin: A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19.Angiotensin II Type 2 Receptor Blockers: Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.Angiotensins: Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANGIOTENSIN SYSTEM. These include angiotensins derived naturally from precursor ANGIOTENSINOGEN, and those synthesized.Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.Enalaprilat: The active metabolite of ENALAPRIL and a potent intravenously administered angiotensin-converting enzyme inhibitor. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.Biphenyl CompoundsSaralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.Teprotide: A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent.Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.Imidazoles: Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.Benzimidazoles: Compounds with a BENZENE fused to IMIDAZOLES.Cilazapril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.1-Sarcosine-8-Isoleucine Angiotensin II: An ANGIOTENSIN II analog which acts as a highly specific inhibitor of ANGIOTENSIN TYPE 1 RECEPTOR.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.ThiazepinesAldosterone: A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.Bradykinin: A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.Vasoconstrictor Agents: Drugs used to cause constriction of the blood vessels.Rats, Inbred SHR: A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke.Diuretics: Agents that promote the excretion of urine through their effects on kidney function.Angiotensinogen: An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver and secreted into blood circulation. Angiotensinogen is the inactive precursor of natural angiotensins. Upon successive enzyme cleavages, angiotensinogen yields angiotensin I, II, and III with amino acids numbered at 10, 8, and 7, respectively.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Tetrahydroisoquinolines: A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.Adrenergic beta-Antagonists: Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.Imidazolidines: Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring.Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.Rats, Inbred WKY: A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR).Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.3-Mercaptopropionic Acid: An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.Kinins: A generic term used to describe a group of polypeptides with related chemical structures and pharmacological properties that are widely distributed in nature. These peptides are AUTACOIDS that act locally to produce pain, vasodilatation, increased vascular permeability, and the synthesis of prostaglandins. Thus, they comprise a subset of the large number of mediators that contribute to the inflammatory response. (From Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th ed, p588)Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Angioedema: Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.Pyridines: Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.Renal Circulation: The circulation of the BLOOD through the vessels of the KIDNEY.Fosinopril: A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.Receptors, Bradykinin: Cell surface receptors that bind BRADYKININ and related KININS with high affinity and trigger intracellular changes which influence the behavior of cells. The identified receptor types (B-1 and B-2, or BK-1 and BK-2) recognize endogenous KALLIDIN; t-kinins; and certain bradykinin fragments as well as bradykinin itself.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.Muscle, Smooth, Vascular: The nonstriated involuntary muscle tissue of blood vessels.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Angiotensin Amide: The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction.Hypertension, Renovascular: Hypertension due to RENAL ARTERY OBSTRUCTION or compression.Calcium Channel Blockers: A class of drugs that act by selective inhibition of calcium influx through cellular membranes.Myocardium: The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.Vasoconstriction: The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Benzoates: Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.Diet, Sodium-Restricted: A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed)Oligopeptides: Peptides composed of between two and twelve amino acids.Heart Rate: The number of times the HEART VENTRICLES contract per unit of time, usually per minute.Mineralocorticoid Receptor Antagonists: Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.Aorta: The main trunk of the systemic arteries.Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)Chymases: A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.Nephrectomy: Excision of kidney.Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.Receptor, Bradykinin B2: A constitutively expressed subtype of bradykinin receptor that may play a role in the acute phase of the inflammatory and pain response. It has high specificity for intact forms of BRADYKININ and KALLIDIN. The receptor is coupled to G-PROTEIN, GQ-G11 ALPHA FAMILY and G-PROTEIN, GI-GO ALPHA FAMILY signaling proteins.Glomerular Filtration Rate: The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.Indoles: Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.Rats, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Drinking: The consumption of liquids.Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Vascular Resistance: The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Sodium Chloride Symporter Inhibitors: Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Benzazepines: Compounds with BENZENE fused to AZEPINES.Kidney Glomerulus: A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.Sodium: A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
... , sold under the trade name Capoten, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of ... Brown, NJ; Vaughan, DE (1998). "Angiotensin-converting enzyme inhibitors". Circulation. 97 (14): 1411-20. doi:10.1161/01.cir. ... "Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents". Science. ... "A new class of angiotensin-converting enzyme inhibitors". Nature. 288 (5788): 280-3. doi:10.1038/288280a0. PMID 6253826. " ...
Angiotensin-converting-enzyme inhibitors, or ACE inhibitors, are a class of widely-prescribed medications used in hypertension ... "What Is an Angiotensin Converting Enzyme Inhibitor?". Circulation. 108 (3): e16-18. doi:10.1161/01.CIR.0000075957.16003.07.. ... as have small peptides that inhibit angiotensin-1-converting enzyme;[a] the venom of the redback, although little-studied, ... It contains a complex mixture of cellular constituents, enzymes and a number of high-molecular-weight toxins, including insect ...
"Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor ... Ruconest (C1-inhibitor). References[edit]. *^ a b c d e f g h i j k l m n o p q r s t Bernstein, JA; Cremonesi, P; Hoffmann, TK ... Sabroe RA, Black AK (February 1997). "Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema". British Journal of ... Israili ZH, Hall WD (August 1, 1992). "Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor ...
These include the angiotensin-converting enzyme inhibitor captopril. Captopril is based on the peptidic bradykinin potentiating ... Enzymes in turn are composed of amino acids and often non-peptidic cofactors that are essential for enzyme function. The basic ... In animals, the three carbon precursors lactate or glycerol can be converted into pyruvate which in turn can be converted into ... they possess enzymes that are functional under quite unusual conditions. These enzymes are of potential use in the food, ...
"Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor ... Sabroe RA, Black AK (February 1997). "Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema". British Journal of ... Israili ZH, Hall WD (August 1, 1992). "Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor ... Dykewicz, MS (August 2004). "Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms ...
... is an ACE Inhibitor, meaning it blocks the actions of angiotensin converting enzyme (ACE) in the renin-angiotensin- ... Lisinopril is a drug of the angiotensin-converting enzyme (ACE) inhibitor class used primarily in treatment of high blood ... John Wiley & Sons, Apr 3, 2013 ISBN 9781118354469 Menard J and Patchett A. "Angiotensin-Converting Enzyme Inhibitors". pp. 14- ... 1980). "A new class of angiotensin-converting enzyme inhibitors". Nature. 288 (5788): 280-3. Bibcode:1980Natur.288..280P. doi: ...
Angiotensin-converting enzyme (ACE) inhibitors can also be used. The limited prognostic information available suggests that ...
"Ecallantide for the acute treatment of Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, ... "Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors". American Journal of Health-System ... HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a ... It is an inhibitor of the protein kallikrein and a 60-amino acid polypeptide which was developed from a Kunitz domain through ...
It is an angiotensin converting enzyme inhibitor (ACE inhibitor), which inhibits the conversion of angiotensin I to angiotensin ... It was found that teprotide inhibits the enzyme that converts angiotensin I to angiotensin II. From this researchers conducted ... "Angiotensin-converting enzyme inhibitors from the venom of bothrops jararaca. Isolation, elucidation of structure, and ... "History of the design of captopril and related inhibitors of angiotensin converting enzyme". Hypertension. 17 (4): 589-592. doi ...
The mushroom contains nicotianamine, an ACE inhibitor (angiotensin-converting enzyme). Nicotianamine is a metal-chelating ... Izawa H, Aoyagi Y (2006). "Inhibition of angiotensin converting enzyme by mushroom". Journal of the Japanese Society for Food ...
However, Angiotensin converting enzyme inhibitors and Angiotensin II receptor antagonists are favoured due to their anti- ... Importantly, angiotensin-converting enzyme inhibitors were used in both groups equally. Cyclophosphamide ( traded as endoxan & ...
Takase K, Ikuse T, Aono H, Okahara A (January 1995). "Toxicity study of the angiotensin converting enzyme inhibitor rentiapril ...
Ondetti started work on the isolation of angiotensin-converting enzyme inhibitors. By 1973, work on ACE inhibitors stopped ... Ondetti M A, Rubin B, Cushman D W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active ... Ondetti M A, Sabo E F. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of ... In 1974, Ondetti resumed unofficial work on ACE inhibitors with strong resolve, "We said this was the thing that we had to do ...
It is an angiotensin-converting enzyme (ACE) inhibitor. In small studies, zofenopril appeared significantly more effective in ... Subissi, A; Evangelista, S; Giachetti, A (1999). "Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor ...
"2.5.5.1 Angiotensin-converting enzyme inhibitors". British National Formulary. No. 62. September 2011. Erişim tarihi: 22 Aralık ... Marchesi C, Paradis P, Schiffrin EL (July 2008). "Role of the renin-angiotensin system in vascular inflammation". Trends ... Coca A (2008). "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". ... "Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension". J. ...
Medications in this case may include diuretics and angiotensin-converting enzyme inhibitors. The prognosis of tricuspid ...
Angiotensin-converting enzyme (ACE) inhibitors: Antihypertensive effect of ACE inhibitors may be diminished. ... Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase (COX-2 inhibitor) activity and ...
Angiotensin-converting enzyme (ACE) inhibitors: to lower the blood pressure and improve the heart's pumping ability. ... Angiotensin receptor blockers (ARBs): to provide the benefits of ACE inhibitors for those who can't take ACE inhibitors. ...
... angiotensin-converting enzyme inhibitor). This may occur with the class's better known side effect of dry cough (due to ... www.medicinescomplete.com/mc/bnf/current/PHP1124-angiotensin-converting-enzyme-inhibitors.htm. ...
It is in the angiotensin-converting-enzyme inhibitor (ACEi) family of medications. Enalapril was patented in 1978 and came into ... Normally, angiotensin I is converted to angiotensin II by an angiotensin-converting enzyme (ACE). Angiotensin II constricts ... Last updated April 2011 Menard J and Patchett A. Angiotensin-Converting Enzyme Inhibitors. Pp 14-76 in Drug Discovery and ... Jenny Bryan for The Pharmaceutical Journal, 17 Apr 2009 From snake venom to ACE inhibitor - the discovery and rise of captopril ...
Angioedema can also be drug-induced (most notably, by angiotensin converting enzyme inhibitors). The underlying mechanism can ... of SJS or TEN compared to the general population and have been found to express low levels of the drug metabolizing enzyme ...
"Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough". ... 12S-HpETE, which is the direct precursor to HxA3 and HxB3 in the ALOX12 pathway, may act only after being converted to these ... Genetic polymorphism in the EP3 receptor (rs11209716), has been associated with ACE inhibitor-induce cough in humans. Resolvin ... made by the metabolism of arachidonic acid by any one of several cytochrome P450 enzymes (see Epoxyeicosatrienoic acid) ...
"Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough". ... The ability of endotoxind and IL-1β but not that of PGE2 to trigger fever is blocked by inhibitors of nitric oxide and PG2 EP33 ... Genetic polymorphism in the EP3 receptor (rs11209716), has been associated with ACE inhibitor-induce cough in humans. The use ... pathways that activate phospholipase C to convert cellular phospholipids to diacylglycerol which promotes the activation of ...
Dykewicz, Mark S. (April 2004). "Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into ... They inhibit angiotensin-converting enzyme, which is part of the renin-angiotensin-aldosterone system. Benazepril is a prodrug ... and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs". Am. J. Vet ... ACE inhibitors relax blood vessels, and decrease blood volume, which lowers blood pressure and decreases oxygen demand from the ...
CES1 is responsible for the activation of many prodrugs such as angiotensin-converting enzyme (ACE) inhibitors, oseltamivir, ... focus on angiotensin-converting enzyme inhibitors". Drug Metab Dispos. 42 (1): 126-33. doi:10.1124/dmd.113.053512. PMID ... These enzymes are responsible for the hydrolysis of ester- and amide-bond-containing xenobiotics and drugs such as cocaine and ... This enzyme is known to hydrolyze aromatic and aliphatic esters and can manage cellular cholesterol esterification levels. It ...
Hypertension is treated with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). ... Complications include hypertension due to the activation of the renin-angiotensin-aldosterone system (RAAS), frequent cyst ...
"Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough". ... AM404-an active metabolite of paracetamol-that serves as an anandamide reuptake inhibitor and COX inhibitor also serves as a ... Genetic polymorphism in the EP3 receptor (rs11209716), has been associated with ACE inhibitor-induced cough in humans. Resolvin ... "Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in ...
Angiotensin-Converting Enzyme Inhibitors. Enzyme Inhibitors. Protease Inhibitors. Molecular Mechanisms of Pharmacological ... Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation. The safety and scientific ... Angiotensin converting enzyme (ACE) inhibitor therapy reduces cardiovascular events in patients with coronary artery disease ( ... Effects of Angiotensin Converting Enzyme Inhibitor Therapy on Vascular Inflammation and Compliance. ...
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary ... Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary ... Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary ... Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary ...
Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk ... Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk ... Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk ... Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk ...
Randomised controlled trial of a Calcium Channel or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Regime ... Randomised controlled trial of a Calcium Channel or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Regime ... baseline assessments they will be randomly assigned to treatment with a calcium channel blocker or ACE inhibitor/angiotensin ...
Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well ... The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in ...
... that the complex is an angiotensin-converting enzyme inhibitor-resistant reservoir of angiotensin II-generating activity, and ... 4 Abbreviations used in this paper: ACE, angiotensin converting enzyme; α1ACT, α1-antichymotrypsin; α2M, α2-macroglobulin; AAPF ... chymase appears to be more efficient in this regard than angiotensin-converting enzyme (ACE),4 based on kinetics of hydrolysis ... which can exceed activity of captopril-sensitive angiotensin-converting enzyme. These findings suggest that chymase bound to α2 ...
Angiotensin converting enzyme inhibitors in pregnancy.. Mastrobattista JM1.. Author information. 1. Department of Obstetrics, ... Angiotensin converting enzyme (ACE) inhibitors are excellent antihypertensive agents and are becoming widely used as first-line ... Angiotensin-Converting Enzyme Inhibitors/adverse effects. *Angiotensin-Converting Enzyme Inhibitors/therapeutic use* ... This review discusses the mechanism of action of ACE inhibitors and the use of ACE inhibitors in pregnancy both in experimental ...
Purpose Angiotensin converting enzyme inhibitors (ACEIs) are a group of drugs used to treat hypertension and heart failure, ... Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in ... Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma ... Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997, 136:153-8.PubMedCrossRefGoogle Scholar ...
Pharmacological Actions : Alpha-amylase inhibitor, Alpha-glucosidase inhibitor , Angiotensin-Converting Enzyme Inhibitors, ... Pharmacological Actions : Alpha-amylase inhibitor, Alpha-glucosidase inhibitor , Angiotensin-Converting Enzyme Inhibitors, ... Pharmacological Actions : Angiotensin-Converting Enzyme Inhibitors, Hypotensive, Vascular smooth muscle cell (VSMC) inhibitor ... Pharmacological Actions : Angiotensin-Converting Enzyme Inhibitors, Anti-Angiogenic, Hypotensive, NF-kappaB Inhibitor ...
SEARCH RESULTS for: Angiotensin-converting Enzyme Inhibitors [Drug Class] (839 results) * Share : JavaScript needed for Sharing ...
Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease.. van de Ven PJ1, ... Angiotensin converting enzyme inhibition (ACEi) may impair renal function in such patients, but a prospective study of its ...
Although there are theoretical reasons suggesting that ACE inhibitors might be useful in all patients with heart f ... Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use*. Heart Failure / drug therapy*. Hemodynamics / ... In practice, angiotensin-converting enzyme inhibitors have been shown to given considerable relief to patients with severe ... but the effect is not specific to angiotensin-converting enzyme inhibitors.. ...
Angiotensin converting enzyme inhibitors cause cough in some patients, but the mechanism of this effect is not known. Six ... Nine patients in whom angiotensin converting enzyme inhibitors had not been associated with cough served as controls. In the ... Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors Br Med J (Clin Res Ed ... Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed ...
Renin-Angiotensin System. Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors. Donald R. ... Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in ... effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Amer Heart J. 2004; 148: 747-754. ... Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. ...
Huntingtons disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. Br Med J ( ... Huntingtons disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor.. Br Med J ... Huntingtons disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. ... Huntingtons disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. ...
... nsus Document on) ESC Clinical Practice ... Effects of ACE-inhibitors: Haemodynamic effects, Neurohormonal effects, Antiproliferative effects, Renal effects, Other effects ... Heart failure: Target dose, ACE-I compared with angiotensin, receptor blockers. *Asymptomatic left ventricular systolic ...
Angiotensin-1 converting enzyme inhibitors (ACEIs) improve insulin sensitivity. Inhibitors of dipeptidyl peptidase-4 (DPP-4) ... Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. Eur J Pharmacol. 2019 Sep 03;:172638 Authors: ... Angiotensin-1 converting enzyme inhibitors (ACEIs) improve insulin sensitivity. Inhibitors of dipeptidyl peptidase-4 (DPP-4) ... Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. Eur J Pharmacol. 2019 Sep 03;:172638 Authors: ...
Association between cough and angiotensin-converting enzyme inhibitors versus angiotensin II antagonists: the design of a ... Three Candidate Genes and Angiotensin-Converting Enzyme Inhibitor-Related Cough. A Pharmacogenetic Analysis. Robert Y. L. Zee, ... Three Candidate Genes and Angiotensin-Converting Enzyme Inhibitor-Related Cough. Robert Y. L. Zee, Valluri S. Rao, Robert Z. ... Three Candidate Genes and Angiotensin-Converting Enzyme Inhibitor-Related Cough. Robert Y. L. Zee, Valluri S. Rao, Robert Z. ...
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: Is an ACE always an ace?. Adrian F. Hernandez and Robert ... Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med ... Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure ... Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure ...
Angiotensin-Converting Enzyme (ACE) Inhibitors for High Blood Pressure ... Angiotensin-converting enzyme (ACE) inhibitors block an enzyme needed to form a substance that narrows blood vessels. As a ... Angiotensin-Converting Enzyme (ACE) Inhibitors for High Blood Pressure. Skip to the navigation ... ACE inhibitor cough. A cough is one of the most common side effects of ACE inhibitors. But most people do not get a cough. The ...
Angiotensin-converting enzyme inhibitors, or "ACE" inhibitors, are medications that help relax and widen the blood vessels so ... ACE inhibitors relax vessels, reduce blood pressure. Angiotensin II is a chemical in the body that when produced, enters the ... The presence of angiotensin II also causes a water-retaining hormone to be released, and this increase in fluid retention in ... ACE inhibitors may be used to treat heart, blood vessel, and kidney problems as well as conditions such as migraines and ...
... Information about this medicine. What are the most important things you need to ... Why are ACE inhibitors used?. ACE inhibitors are used for many heart and blood vessel problems. For example, they may be used ... What are some examples of ACE inhibitors?. Here are some examples of ACE inhibitors. For each item in the list, the generic ... Cautions about ACE inhibitors. General cautions for all medicines include the following:. *Allergic reactions: All medicines ...
ACE inhibitors cause your blood vessels to relax - lowering your blood pressure - but there can be some side effects ... Angiotensin converting enzyme (ACE) inhibitors block the effects of a hormone your kidneys naturally produce called angiotensin ... ACE (Angiotensin converting enzyme) inhibitors Increase text size / Decrease text size , Print this page , Email this page ... What can your doctor do > ACE (Angiotensin converting enzyme) inhibitors ...
Angiotensin-Converting Enzyme Inhibitors for Stroke Prevention. Is There HOPE for PROGRESS After LIFE?. Graeme J. Hankey ... Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. ... Lonn EM, Yusuf S, Jha P, Montague TH, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in ... Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a ...
  • Is cozaar (losartan) an ACE inhibitor? (healthtap.com)
  • In patients who had type 2 diabetes and overt nephropathy and were enrolled in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and in the Irbesartan Diabetic Nephropathy Trial (IDNT), there was a significant relationship between the BP levels that were achieved during the follow-up period and the incidence of ESRD or cardiovascular events ( 3 , 4 ). (asnjournals.org)
  • In the presence of an ACE2 specific inhibitor, the enzyme loses its peptidase activity which results in decrease of fluorescence intensity. (creativebiomart.net)
  • In an extensive study, we present high-resolution structures for native AnCE and in complex with six known antihypertensive drugs, a novel C-domain sACE specific inhibitor, lisW-S, and two sACE domain-specific phosphinic peptidyl inhibitors, RXPA380 and RXP407 (i.e., nine structures). (bath.ac.uk)
  • DX600 TFA is an ACE2 specific inhibitor, and do not cross-react with ACE. (medchemexpress.com)
  • Azd 6244- mek inhibitor- a selective mitogen-activated protein kinase (mek) inhibitor. (healthtap.com)
  • The design of inhibitors that selectively inhibit the N-domain (N-selective) could be useful in treating conditions of tissue injury and fibrosis due to build-up of N-domain-specific substrate Ac-SDKP ( N -acetyl-Ser-Asp-Lys-Pro). (clinsci.org)
  • Using a receptor-based SHOP (scaffold hopping) approach with N-selective inhibitor RXP407, a shortlist of scaffolds that consisted of modified RXP407 backbones with novel chemotypes was generated. (clinsci.org)
  • This work further elucidates the molecular basis for N-domainselective inhibition and assists in the design of novel N-selective ACE inhibitors that could be employed in treatment of fibrosis disorders. (clinsci.org)
  • Crystal structures of both ACE domains (nACE and cACE) reported over the last decades could facilitate the rational drug design of selective inhibitors. (eurekaselect.com)
  • We stated that the design of novel selective ACE inhibitors is a challenge for current researchers which requires a thorough understanding of the structure of both ACE domains and the help of molecular modeling methodologies. (eurekaselect.com)
  • This review discusses the mechanism of action of ACE inhibitors and the use of ACE inhibitors in pregnancy both in experimental animals and use in human pregnancy. (nih.gov)
  • It was the first ACE inhibitor developed and was considered a breakthrough both because of its novel mechanism of action and also because of the revolutionary development process. (wikipedia.org)
  • The results of the HOPE and LIFE trials, and to a lesser extent SCOPE, indicate that inhibiting the formation or action of angiotensin II prevents stroke and other vascular events (and perhaps new-onset diabetes) and suggest that a substantial proportion of the effect may be independent of BP lowering. (ahajournals.org)
  • The experiment was carried out using the Beckman PACE system and steps were taken to determine (a) the migration profiles of angiotensin and its yielded peptides, (b) the minimal amount of angiotensin II detected, (c) the use of different electrolytes and (d) the concentration of inhibitor. (ox.ac.uk)
  • Since des-Arg9-BK is produced from BK by carboxypeptidase M along cell surface, we hypothesize that the blockade of the enzyme may also reduce the vascular leakage being a new potential target. (trieste.it)
  • Out of this cohort, 209 infants with exposure to ACE inhibitors in the first trimester were identified. (motherisk.org)
  • Earlier work from Pilote and colleagues also suggests that ACE inhibitors may not have a class effect. (cmaj.ca)
  • More recent research suggests that ACE inhibitors can reduce risk of Alzheimer's disease in the absence of apolipoprotein E4 alleles (ApoE4), but will have no effect in ApoE4- carriers. (wikipedia.org)
  • However, animal data reveal increased morbidity and mortality in fetuses exposed to ACE inhibitors in utero. (motherisk.org)
  • Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. (medchemexpress.com)
  • The aim of the proposal is to thoroughly identify the mechanisms leading to the enhanced vascular permeability in clinical settings of AE by focusing not only on C1-INH deficiency as a primary disease model but also on ACE-inhibitor related AE in order to identify new possible therapeutic tools. (trieste.it)